Alpha Cognition Inc. appointed Bethany Sensenig as a new member of the Board of Directors effective April 15, 2026. Ms. Sensenig brings extensive experience in biopharmaceutical financial leadership, including roles at Radius Health, 9 Meters Biopharma, and Biogen. The appointment includes an initial equity grant of 5,489 restricted stock units and 6,991 stock options with an exercise price of $6.65 per share. The equity grants are subject to a one-year vesting period.